Thank you for the opportunity to review this paper.

The authors analyzed a prespecified outcome of a RCT comparing liraglutide vs. placebo.

Follow-up was 26 weeks and the focus was on cardiac neuropathy.

The paper is well written and presented. However, there is little significant difference in the outcomes. Furthermore, for the outcomes that are significant, it is highly questionable whether they are clinically relevant.

From a methodological standpoint and presentation, the study is nicely done and well made.

However, the clinical relevance is missing due to the short follow-up and the minimal changes.

Thank you for the well done revisions.

However, I suggest that you make a post-hoc power calculation to determine how many patients would be needed in a trial to demonstrate a beneficial effect of liraglutide on CARTs.

Several reviewers including me pointed out the small cohort. However, as you have referenced in the response, there are studies with smaller cohorts, similar follow up and same methodology that showed an improvement in CARTs.

Therefore, it should be discussed that liraglutide may just not be effective for treatment of CARTs. A post-hoc power calculation would help to appreciate the effectiveness and the feasibility of a RCT aiming to answer this question.